Infectious complications within the first year after nonmyeloablative allogeneic peripheral blood stem cell transplantation

S. B. Mossad, Robin Avery, D. L. Longworth, E. M. Kuczkowski, M. McBee, B. L. Pohlman, R. M. Sobecks, M. E. Kalaycio, S. W. Andresen, R. M. Macklis, B. J. Bolwell

Research output: Contribution to journalArticle

Abstract

Nonmyeloablative peripheral blood stem cell transplantation (PBSCT) is a novel therapeutic strategy for patients with malignant and non-malignant hematologic diseases. Infectious complications of this procedure have not been previously well described. Data on 12 patients transplanted at a tertiary care center were collected prospectively and verified retrospectively. Neutropenia developed in a third of patients, lasting for a median of 5 days. All patients developed some degree of graft-versus-host disease, as intended. Most patients achieved full chimerism by week 5. Bacterial infections occurred in two patients (17%). Cytomegalovirus (CMV) viremia occurred in five patients (42%) at a median of 80 days; none had received CMV prophylaxis. Viremia was associated with fever and fatigue in three patients, possible gastrointestinal involvement in one patient and was asymptomatic in one patient. All viremic patients responded to intravenous ganciclovir therapy. No fungal infections were documented. No patients died as a result of infection. The incidence of CMV viremia in our patients was high, but the incidence of invasive disease due to CMV was low. The best strategy to prevent CMV in patients undergoing nonmyeloablative PBSCT remains to be determined, but strategies employed in traditional allogeneic bone marrow transplantation should be considered in these patients.

Original languageEnglish (US)
Pages (from-to)491-495
Number of pages5
JournalBone Marrow Transplantation
Volume28
Issue number5
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Peripheral Blood Stem Cell Transplantation
Cytomegalovirus
Viremia
Chimerism
Ganciclovir
Mycoses
Hematologic Diseases
Incidence
Homologous Transplantation
Graft vs Host Disease
Neutropenia
Bone Marrow Transplantation
Bacterial Infections

Keywords

  • Bone marrow transplantation
  • Infection
  • Nonmyeloablative conditioning

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Infectious complications within the first year after nonmyeloablative allogeneic peripheral blood stem cell transplantation. / Mossad, S. B.; Avery, Robin; Longworth, D. L.; Kuczkowski, E. M.; McBee, M.; Pohlman, B. L.; Sobecks, R. M.; Kalaycio, M. E.; Andresen, S. W.; Macklis, R. M.; Bolwell, B. J.

In: Bone Marrow Transplantation, Vol. 28, No. 5, 2001, p. 491-495.

Research output: Contribution to journalArticle

Mossad, SB, Avery, R, Longworth, DL, Kuczkowski, EM, McBee, M, Pohlman, BL, Sobecks, RM, Kalaycio, ME, Andresen, SW, Macklis, RM & Bolwell, BJ 2001, 'Infectious complications within the first year after nonmyeloablative allogeneic peripheral blood stem cell transplantation', Bone Marrow Transplantation, vol. 28, no. 5, pp. 491-495. https://doi.org/10.1038/sj.bmt.1703180
Mossad, S. B. ; Avery, Robin ; Longworth, D. L. ; Kuczkowski, E. M. ; McBee, M. ; Pohlman, B. L. ; Sobecks, R. M. ; Kalaycio, M. E. ; Andresen, S. W. ; Macklis, R. M. ; Bolwell, B. J. / Infectious complications within the first year after nonmyeloablative allogeneic peripheral blood stem cell transplantation. In: Bone Marrow Transplantation. 2001 ; Vol. 28, No. 5. pp. 491-495.
@article{89e6791de4dc4ab89fc29e4e5089f30e,
title = "Infectious complications within the first year after nonmyeloablative allogeneic peripheral blood stem cell transplantation",
abstract = "Nonmyeloablative peripheral blood stem cell transplantation (PBSCT) is a novel therapeutic strategy for patients with malignant and non-malignant hematologic diseases. Infectious complications of this procedure have not been previously well described. Data on 12 patients transplanted at a tertiary care center were collected prospectively and verified retrospectively. Neutropenia developed in a third of patients, lasting for a median of 5 days. All patients developed some degree of graft-versus-host disease, as intended. Most patients achieved full chimerism by week 5. Bacterial infections occurred in two patients (17{\%}). Cytomegalovirus (CMV) viremia occurred in five patients (42{\%}) at a median of 80 days; none had received CMV prophylaxis. Viremia was associated with fever and fatigue in three patients, possible gastrointestinal involvement in one patient and was asymptomatic in one patient. All viremic patients responded to intravenous ganciclovir therapy. No fungal infections were documented. No patients died as a result of infection. The incidence of CMV viremia in our patients was high, but the incidence of invasive disease due to CMV was low. The best strategy to prevent CMV in patients undergoing nonmyeloablative PBSCT remains to be determined, but strategies employed in traditional allogeneic bone marrow transplantation should be considered in these patients.",
keywords = "Bone marrow transplantation, Infection, Nonmyeloablative conditioning",
author = "Mossad, {S. B.} and Robin Avery and Longworth, {D. L.} and Kuczkowski, {E. M.} and M. McBee and Pohlman, {B. L.} and Sobecks, {R. M.} and Kalaycio, {M. E.} and Andresen, {S. W.} and Macklis, {R. M.} and Bolwell, {B. J.}",
year = "2001",
doi = "10.1038/sj.bmt.1703180",
language = "English (US)",
volume = "28",
pages = "491--495",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Infectious complications within the first year after nonmyeloablative allogeneic peripheral blood stem cell transplantation

AU - Mossad, S. B.

AU - Avery, Robin

AU - Longworth, D. L.

AU - Kuczkowski, E. M.

AU - McBee, M.

AU - Pohlman, B. L.

AU - Sobecks, R. M.

AU - Kalaycio, M. E.

AU - Andresen, S. W.

AU - Macklis, R. M.

AU - Bolwell, B. J.

PY - 2001

Y1 - 2001

N2 - Nonmyeloablative peripheral blood stem cell transplantation (PBSCT) is a novel therapeutic strategy for patients with malignant and non-malignant hematologic diseases. Infectious complications of this procedure have not been previously well described. Data on 12 patients transplanted at a tertiary care center were collected prospectively and verified retrospectively. Neutropenia developed in a third of patients, lasting for a median of 5 days. All patients developed some degree of graft-versus-host disease, as intended. Most patients achieved full chimerism by week 5. Bacterial infections occurred in two patients (17%). Cytomegalovirus (CMV) viremia occurred in five patients (42%) at a median of 80 days; none had received CMV prophylaxis. Viremia was associated with fever and fatigue in three patients, possible gastrointestinal involvement in one patient and was asymptomatic in one patient. All viremic patients responded to intravenous ganciclovir therapy. No fungal infections were documented. No patients died as a result of infection. The incidence of CMV viremia in our patients was high, but the incidence of invasive disease due to CMV was low. The best strategy to prevent CMV in patients undergoing nonmyeloablative PBSCT remains to be determined, but strategies employed in traditional allogeneic bone marrow transplantation should be considered in these patients.

AB - Nonmyeloablative peripheral blood stem cell transplantation (PBSCT) is a novel therapeutic strategy for patients with malignant and non-malignant hematologic diseases. Infectious complications of this procedure have not been previously well described. Data on 12 patients transplanted at a tertiary care center were collected prospectively and verified retrospectively. Neutropenia developed in a third of patients, lasting for a median of 5 days. All patients developed some degree of graft-versus-host disease, as intended. Most patients achieved full chimerism by week 5. Bacterial infections occurred in two patients (17%). Cytomegalovirus (CMV) viremia occurred in five patients (42%) at a median of 80 days; none had received CMV prophylaxis. Viremia was associated with fever and fatigue in three patients, possible gastrointestinal involvement in one patient and was asymptomatic in one patient. All viremic patients responded to intravenous ganciclovir therapy. No fungal infections were documented. No patients died as a result of infection. The incidence of CMV viremia in our patients was high, but the incidence of invasive disease due to CMV was low. The best strategy to prevent CMV in patients undergoing nonmyeloablative PBSCT remains to be determined, but strategies employed in traditional allogeneic bone marrow transplantation should be considered in these patients.

KW - Bone marrow transplantation

KW - Infection

KW - Nonmyeloablative conditioning

UR - http://www.scopus.com/inward/record.url?scp=0035161450&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035161450&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1703180

DO - 10.1038/sj.bmt.1703180

M3 - Article

C2 - 11593323

AN - SCOPUS:0035161450

VL - 28

SP - 491

EP - 495

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 5

ER -